Clinical outcomes associated with prior glucagon-like peptide-1 receptor agonist exposure in burned patients.
Prior GLP-1 receptor agonist use associated with lower odds of death after burn injury
Clinical outcomes associated with prior glucagon-like peptide-1 receptor agonist exposure in burned patients.
Glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and immunomodulatory properties beyond glycaemic control.
The aim of this study was to assess the potential impact of prior GLP-1 receptor agonist exposure on mortality, infectious complications, and critical care utilization in burn patients.
With documented GLP-1 receptor agonist use within 1 year before burn injury were propensity score matched with controls for age, sex, race, co-morbidities, total body surface area, BMI, and haemoglobin A1c (HbA1c).
prior GLP-1 use nearly halved the odds of death after burn injury
Infectious complications were significantly decreased, including sepsis (32% reduction), pneumonia (24% reduction), and methicillin-resistant Staphylococcus aureus (methicillin-resistant Staphylococcus aureus) infection (27% reduction).
The odds of broad-spectrum antibiotic use decreased 21%.
Benefits persisted across all exposure windows.
The 3-year cohort demonstrated a 27% increase in hypertrophic scarring (OR 1.27, P = 0.031).
Prior GLP-1 receptor agonist use was associated with a significant decrease in mortality, infectious complications, and critical care utilization among burn patients, independent of metabolic factors like BMI.
These findings warrant prospective studies to optimize perioperative management strategies in this patient population.